Fortress Biotech, Inc.
FBIO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | 0.01 | -0.03 | -0.15 |
| FCF Yield | -225.62% | -558.38% | -311.05% | -65.06% |
| EV / EBITDA | -0.58 | -0.24 | -0.04 | 0.18 |
| Quality | ||||
| ROIC | -145.47% | -155.12% | -113.82% | -62.43% |
| Gross Margin | 63.80% | 72.91% | 59.37% | 53.36% |
| Cash Conversion Ratio | 0.66 | 0.83 | 0.84 | 0.71 |
| Growth | ||||
| Revenue 3-Year CAGR | -8.68% | 7.10% | 18.43% | 23.38% |
| Free Cash Flow Growth | 30.17% | 25.28% | -37.30% | -46.28% |
| Safety | ||||
| Net Debt / EBITDA | -0.18 | -0.06 | 0.26 | 1.58 |
| Interest Coverage | -11.12 | -11.37 | -14.92 | -12.32 |
| Efficiency | ||||
| Inventory Turnover | 1.45 | 2.24 | 2.17 | 3.25 |
| Cash Conversion Cycle | -234.94 | -325.82 | -374.40 | -301.15 |